Permira subsidiary Neuraxpharm acquires two product portfolios from Sanofi
Frankfurt a. M. — The Neuraxpharm Group has acquired two product portfolios from Sanofi, which are marketed globally in over 50 countries. With the pending acquisition, Neuraxpharm aims to strengthen its position as a leading European specialty pharmaceutical company focused on central nervous system disorders and expand its global footprint. The acquisition of the portfolios will increase Neuraxpharm’s annual gross sales to approximately €0.6 billion. — International law firm Clifford Chance advised Neuraxpharm Group on the acquisition of the two product portfolios from Sanofi.
The initial portfolio includes a range of products targeting central nervous system disorders, covering the areas of psychiatry and neurology — including the drugs Nozinan, Tranxene, Tiapridal, Dogmatil and Largactil. The second portfolio includes Topalgic and Trental, two products for the treatment of pain and vascular diseases. The drugs are used in a variety of patients with different conditions, including depression, anxiety, psychosis, alcohol dependence, myasthenia gravis and Parkinson’s disease. Both product portfolios comprise 17 molecules marketed under 38 brands.
Neuraxpharm is a portfolio group of the private equity fund Permira. Clifford Chance had already advised global private equity firm Permira on the acquisition of Neuraxpharm Group in 2020.
Advisor Neuraxpharm Group: Clifford Chance
Led by partner Dr. Jörg Rhiel (Corporate/Private Equity, Frankfurt).
About Clifford Chance
Clifford Chance, one of the world’s leading law firms, is present for its clients with around 3,400 legal advisors in all major business centers around the world.
In Germany, Clifford Chance is represented by around 300 lawyers, auditors, tax advisors and solicitors in Düsseldorf, Frankfurt am Main and Munich.